Guard Therapeutics Intl (GUARD) investor relations material

Executive summary

• Operations scaled down after discontinuation of the RMC-035 clinical program due to negative phase 2b results, leading to a strategic review focused on identifying merger or reverse acquisition opportunities.

• The company currently maintains minimal operational activity, with a primary focus on cost control and preservation of cash during the ongoing strategic process.

• If no transaction is completed, a controlled liquidation with distribution of remaining funds to shareholders is considered.

Financial highlights

• Net sales for Q1 2026 were 0 KSEK, unchanged from the previous year.

• Net result before and after tax was -6,351 KSEK, a significant improvement from -34,215 KSEK year-over-year.

• Earnings per share were -0.31 SEK, compared to -2.78 SEK in Q1 2025.

• Cash and cash equivalents at quarter-end were 40,995 KSEK, up from 16,096 KSEK a year earlier.

• Operating cash flow for Q1 was -8,896 KSEK, compared to -35,901 KSEK in Q1 2025.

Outlook and guidance

• No further significant project costs related to clinical or preclinical development are expected to impact results in Q2.

• The strategic review is in its final phase, with a decision on the company's future direction expected soon.